Anti-ADM therapy with ADM-neutralizing antibodies, ADM receptor antagonists, or ADM receptor interference might be a promising strategy to be explored in ovarian cancer, not only as an antiangiogenic alternative in the context of acquired resistance to vascular endothelial growth factor (VEGF) treatment, but also as a potential metabolism-related approach. This evidence concerns the gene VEGFA and ovarian carcinoma.